Attovia Therapeutics, Inc. (ATTO) – What Are Researchers Thinking About This Stock?

Attovia Therapeutics, Inc. (NASDAQ:ATTO) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $42.20.

A number of research analysts recently issued reports on the company. Lifesci Capital initiated coverage on Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $45.00 price target on the stock. Leerink Partners assumed coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $52.00 price objective for the company. Morgan Stanley assumed coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued an “overweight” rating and a $39.00 price objective for the company. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Zacks Research upgraded Attovia Therapeutics to a “hold” rating in a research report on Friday, September 4th.

Attovia Therapeutics Stock Performance

Shares of Attovia Therapeutics stock opened at $16.21 on Friday. The stock has a fifty day moving average price of $20.56. Attovia Therapeutics has a 12-month low of $15.48 and a 12-month high of $28.00. The company has a market cap of $739.99 million and a price-to-earnings ratio of -3.32.

Attovia Therapeutics (NASDAQ:ATTO) last issued its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The firm had revenue of $0.45 million for the quarter. As a group, sell-side analysts expect that Attovia Therapeutics will post -4.06 earnings per share for the current year.

Insider Activity at Attovia Therapeutics

In related news, major shareholder Global Strategic Fund I. Venbio purchased 382,352 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,499,984.00. Following the completion of the acquisition, the insider directly owned 4,181,367 shares in the company, valued at approximately $71,083,239. The trade was a 10.06% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Redmile Group, Llc acquired 400,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the transaction, the insider owned 1,182,854 shares in the company, valued at approximately $20,108,518. This trade represents a 51.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 2,740,587 shares of company stock valued at $47,269,979 over the last 90 days. Company insiders own 0.99% of the company’s stock.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc is a clinical-stage biotechnology company developing antibody-based medicines for immune-mediated and inflammatory diseases. The company uses proprietary antibody-engineering technologies to design therapies intended to modulate biological pathways involved in chronic inflammation.

Attovia’s development pipeline includes ATTO-1310, an investigational antibody therapy being advanced for atopic dermatitis and potentially other inflammatory conditions. The company’s broader research efforts focus on developing treatments that may offer targeted activity and durable effects for patients with immune-related diseases.

Attovia Therapeutics is advancing its programs through preclinical and clinical development and has not yet established a commercial product portfolio.